Author:
Zhang Bo,Liu Renwang,Ren Dian,Li Xiongfei,Wang Yanye,Huo Huandong,Zhu Shuai,Chen Jun,Song Zuoqing,Xu Song
Abstract
BackgroundTo investigate the differences in survival between lobectomy and sub-lobar resection for elderly stage I non-small-cell lung cancer (NSCLC) patients using the Surveillance, Epidemiology, and End Results (SEER) registry.MethodThe data of stage IA elderly NSCLC patients (≥ 70 years) with tumors less than or equal to 3 cm in diameter were extracted. Propensity-matched analysis was used. Lung cancer-specific survival (LCSS) was compared among the patients after lobectomy and sub-lobar resection. The proportional hazards model was applied to identify multiple prognostic factors.ResultsA total of 3,504 patients met criteria after propensity score matching (PSM). Although the LCSS was better for lobectomy than for sub-lobar resection in patients with tumors ≤ 3 cm before PSM (p < 0.001), no significant difference in the LCSS was identified between the two treatment groups after PSM (p = 0.191). Multivariate Cox regression showed the elder age, male gender, squamous cell carcinoma (SQC) histology type, poor/undifferentiated grade and a large tumor size were associated with poor LCSS. The subgroup analysis of tumor sizes, histologic types and lymph nodes (LNs) dissection, there were also no significant difference for LCSS between lobectomy and sub-lobar resection. The sub-lobar resection was further divided into segmentectomy or wedge resection, and it demonstrated that no significant differences in LCSS were identified among the treatment subgroups either. Multivariate Cox regression analysis showed that the elder age, poor/undifferentiated grade and a large tumor size were a statistically significant independent factor associated with survival.ConclusionIn terms of LCSS, lobectomy has no significant advantage over sub-lobar resection in elderly patients with stage IA NSCLC if lymph node assessment is performed adequately. The present data may contribute to develop a more suitable surgical treatment strategy for the stage IA elderly NSCLC patients.
Funder
National Natural Science Foundation of China
Tianjin Science and Technology Committee
Reference34 articles.
1. Cancer Statistics, 2019;Siegel;CA Cancer J Clin,2019
2. Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer;Church;N Engl J Med,2013
3. Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database;Govindan;J Clin Oncol,2006
4. Cancer Treatment and Survivorship Statistics, 2019;Miller;CA Cancer J Clin,2019
5. Thoracic Radiotherapy With or Without Daily Low-Dose Carboplatin in Elderly Patients With non-Small-Cell Lung Cancer: A Randomised, Controlled, Phase 3 Trial by the Japan Clinical Oncology Group (Jcog0301);Atagi;Lancet Oncol,2012
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献